US Patent Issued to SHANGHAI MINWEI BIOTECHNOLOGY on Sept. 8 for "Fusion protein having triple activity and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,231, issued on Sept. 8, was assigned to SHANGHAI MINWEI BIOTECHNOLOGY Co. LTD (Shanghai).

"Fusion protein having triple activity and use thereof" was invented by Weiyue Han (Shanghai), Guitao Zhang (Shanghai), Dixiang Luo (Shanghai), Wenxin Song (Shanghai), Shaodong Zhong (Shanghai), Dan Liu (Shanghai) and Jiangtao Peng (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can ...